Repare Therapeutics Inc.
RPTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $12 | $0 | $0 | $0 |
| % Growth | 4,548% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $1 | $0 |
| Gross Profit | $12 | $0 | -$1 | -$0 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $8 | $14 | $19 | $24 |
| G&A Expenses | $5 | $6 | $0 | $0 |
| SG&A Expenses | $5 | $6 | $8 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | -$2 | $0 | $0 |
| Operating Expenses | $10 | $18 | $27 | $30 |
| Operating Income | $1 | -$18 | -$28 | -$31 |
| % Margin | 9.7% | -7,112% | – | – |
| Other Income/Exp. Net | $2 | $1 | -$2 | $2 |
| Pre-Tax Income | $3 | -$16 | -$30 | -$29 |
| Tax Expense | $0 | $0 | $1 | $0 |
| Net Income | $3 | -$17 | -$30 | -$29 |
| % Margin | 28% | -6,697.6% | – | – |
| EPS | 0.08 | -0.39 | -0.71 | -0.67 |
| % Growth | 120.5% | 45.1% | -6% | – |
| EPS Diluted | 0.08 | -0.39 | -0.71 | -0.67 |
| Weighted Avg Shares Out | 43 | 43 | 43 | 42 |
| Weighted Avg Shares Out Dil | 43 | 43 | 43 | 42 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $2 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $0 |
| EBITDA | $3 | -$19 | -$28 | -$28 |
| % Margin | 29.9% | -7,610.4% | – | – |